Article information
Full text is only aviable in PDF
Bibliografía
[1.]
A.T. Turrisi, K. Kim, R. Blum, et al.
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
N Engl J Med, 340 (1999), pp. 265-271
[2.]
J.A. Bonner, J.A. Sloan, T.h.G. Shanahan, et al.
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.
J Clin Oncol, 17 (1999), pp. 2681-2691
[3.]
K. Furuse, M. Fukuoka, M. Kawahara, et al.
Phase II study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small cell lung cancer.
J Clin Oncol, 17 (1999), pp. 2692-2699
[4.]
B. Jeremic, Y. Shibamato, S. Acimovic L Milisavljevic.
Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non small cell lung cancer: a randomized study.
J Clin Oncol, 14 (1996), pp. 1065-1070
[5.]
E.K. Rowinsky.
The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agent.
Drugs, 60 (2000), pp. 1-14
[6.]
Angiogenesis and metastasis growth (written in consultation with Judah Folkman) [editorial].
Advances in Oncology, 12 (1996), pp. 2-7
[7.]
A. Yuan, C.H.-.J. Yu, S.-.H. Kuo, et al.
Vascular endotelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival and postoperative relapse in non-small cell lung cancer.
J Clin Oncol, 19 (2001), pp. 441-443
[8.]
E.L. Lund, C.H. Thorsen, M.W.B. Pedersen, N. Junker, P.E.G. Kristjansen.
Relationship between vessel density and expression of vascular endotelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro.
Clin Cancer Res, 6 (2000), pp. 4287-4291
[9.]
C. López Otín.
Metaloproteinasas y progresión tumoral. Encuentros en Oncología (Segovia, 25-26 de marzo de 1999), pp. 15-16
[10.]
B. Passlick, W. Sienel, R. Seen-Hibler, et al.
Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Clin Cancer Res, 6 (2000), pp. 3944-3948
[11.]
M. Birkhofer.
An overview of key compounds from the BMS oncology pipeline: matrix metalloproteinase inhibitor BMS-275291 and epothilone analog BMS-187550.
Encuentros en Oncología (Segovia, 5-6 de abril de 2001), pp. 33-35
[12.]
E. Díaz Rubio.
Oncofarmacogenómica.
Nuevos conceptos en los ensayos clínicos. Encuentros en Oncología, (2001),
[13.]
P. Bunn.
Translation of the biology of lung cancer to targeted therapies.
Educational Book. ASCO 2001. 31st Annual Meeting, (2001),
[14.]
H. Cortés Funes.
Antiangiogenesis agents. Encuentros en Oncología (Segovia, 5-6 de abril de 2001), pp. 29-32
[15.]
K.F. De Vore, L. Fehrenbacher, R.S. Herbst, et al.
A randomized phase II trial comparing Rhumab VEGF plus carboplatin and paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am.
Soc Clin Oncol, 19 (2000), pp. 485
[16.]
F.A. Shepherd, G. Giaccone, C. Debruyne, et al.
Randomized double- blind placebo controlled trial of marimastat in patients with small cell lung cancer following response to first line chemotherapy: an NCI-CTG and EORTC study.
Proc Am Soc Clin Oncol, 20 (2001), pp. 4
[17.]
M. Smylie, R. Mercier, D. Aboulafia, et al.
Phase III study of the matrix metalloproteinase (MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 307
[18.]
M.G. Kris, S.A. Laurie, V.A. Miller.
Integrating new agents and approaches into chemotherapy regimens for non-small cell lung cancers.
Educational Book. ASCO 2000. 30st Annual Meeting, (2000),
[19.]
J. Mendelsohn.
Epidermal growth factor receptor blockade as anticancer therapy.
Educational Book. ASCO 2001. 31st Annual Meeting, (2001),
[20.]
E. Raymond, S. Faivre, J.P. Armand.
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.
Drugs, 60 (2000), pp. 15-23
[21.]
J. Baselga.
New therapeutic agents targeting the epidermal growth factor receptor.
J Clin Oncol, 18 (2000), pp. S54-S59
[22.]
F. Ciardello.
Epidermal growth factor receptor Tyrosine Kinase inhibitors as anticancer agents.
Drugs, 60 (2000), pp. 25-32
[23.]
J. Baselga, S.D. Averbuch.
ZD1839 (“Iressa”) as an anticancer agent.
Drugs, 60 (2000), pp. 33-40
[24.]
K. Nakagawa, N. Yamamoto, S. Kudoh, et al.
A phase I intermittent dose-escalation trial of ZD1839 in Japanese Patients with solid malignant tumours.
Proc Am Soc Clin Oncol, 19 (2000), pp. 183
[25.]
J. Baselga, R. Herbst, P. LoRusso, et al.
Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-TKI) in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Am.
Soc Clin Oncol, 19 (2000), pp. 177
[26.]
D. Ferry, L. Hammond, M. Ranson, et al.
Intermittent oral ZD1389, a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study.
Proc Am Soc Clin Oncol, 19 (2000), pp. 3
[27.]
R. Pérez Soler, A. Chachoua, M. Huberman, et al.
A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-base chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 310
[28.]
L.M. Krug, V.A. Miller, J. Crapanzano, et al.
Randomized phase II trial of Trastuzumab plus either Docetaxel or Paclitaxel in previously untreated advanced non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 333
[29.]
Targeting the BCR-ABL Tyrosine Kinase in chronic myeloid leukemia [editorial].
N Engl J Med, 344 (2001), pp. 1084-1086
[30.]
B.J. Druker, M. Talpaz, D.R. Resta, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med, 344 (2001), pp. 1031-1037
[31.]
B.J. Druker, C.L. Sawyers, H. Kantarjian, et al.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
N Engl J Med, 344 (2001), pp. 1038-1042
[32.]
H. Joensuu, P.J. Roberts, M. Sarlomo-rikala, et al.
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
N Engl J Med, 344 (2001), pp. 1052-1056
[33.]
G.W. Krystal, S. Honsawek, J. Litz, E. Buchdunger.
The Selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Clin Cancer Res, 6 (2000), pp. 3319-3326
[34.]
L.H. Camacho, S.L. Soignet, S. Pezzulli, et al.
Dose escalation of oral Farnesyl transferase inhibitor (FTI) BMS-214682 in patients with solid tumors. Proc Am.
Soc Clin Oncol, 20 (2001), pp. 79
[35.]
K.B. Kim, D.M. Shin, C.C. Summey, et al.
Phase I study of Farnesyl transferase inhibitor, BMS-214662 in solid tumors.
Proc Am Soc Clin Oncol, 20 (2001), pp. 79
[36.]
M. Voi, J. Tabernero, M.R. Cooper, et al.
A phase I study of the Farnesyl transferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients with advanced solid tumors: clinical findings.
Proc Am Soc Clin Oncol, 20 (2001), pp. 79
[37.]
H.J. Mackay, R. Hoekstra, F. Eskens, et al.
A phase I dose escalating study of BMS-214662 with cisplatin in patients with advanced solid tumors.
Proc Am Soc Clin Oncol, 20 (2001), pp. 80
[38.]
K. Nakagawa, N. Yamamoto, K. Nishio, et al.
A phase I pharmacokinetic and pharmacodynamic study of the Farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies.
Proc Am Soc Clin Oncol, 20 (2001), pp. 80
[39.]
M.J. Piccart-Gebhart, F. Branle, D. De Valerola, et al.
A phase I. clinical and pharmacokinetic trial of the Farnesyl transferase inhibitor (FTI) R115777 + Docetaxel: a promising combination in patients with solid tumors.
Proc Am Soc Clin Oncol, 20 (2001), pp. 80
[40.]
L. Liebes, H. Hochster, J. Speyer, et al.
Enhanced myelosuppression of Topotecan when combined with the Farnesyl transferase inhibitor, R115777: a phase I & pharmacodynamic study.
Proc Am Soc Clin Oncol, 20 (2001), pp. 81
[41.]
A.A. Adjer, C. Erlichman, R.S. Marks, et al.
A phase I trial of the Farnesyl transferase inhibitor, R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 81
[42.]
G. Fisher, R. Advani, M. Moore, et al.
Phase I/II trial of ISIS 3521, an antisense inhibitir of PKC-alpha, with Carboplatin and Paclitaxel in non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 309
Copyright © 2002. Sociedad Española de Neumología y Cirugía Torácica
